CervoMed Past Earnings Performance
Past criteria checks 0/6
CervoMed has been growing earnings at an average annual rate of 62.6%, while the Biotechs industry saw earnings growing at 12.3% annually.
Key information
62.6%
Earnings growth rate
92.7%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -29.4% |
| Net Margin | -30.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Revenue & Expenses BreakdownBeta
How CervoMed makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 7 | -2 | 6 | 0 |
| 30 Sep 23 | 5 | -1 | 5 | 1 |
| 31 Mar 23 | 1 | -6 | 3 | 1 |
| 31 Dec 22 | 0 | -6 | 2 | 0 |
Quality Earnings: CRVO is currently unprofitable.
Growing Profit Margin: CRVO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if CRVO's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare CRVO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRVO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CRVO has a negative Return on Equity (-29.44%), as it is currently unprofitable.